Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, Irvine
About this trial
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
Eligibility criteria
Qualifiers
Histologic or radiographic diagnosis of hepatocellular carcinoma
At least one lesion amenable to TACE treatment
Child-Pugh A-B7 (B7 based on Albumin allowed)
Not a candidate for resection or transplantation
Disqualifiers
Any type of previous systemic anti-cancer treatment
All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline
Any locoregional treatment for HCC within 3 months
Vp4 or Vp3 portal vein thrombus
Trial design
Treatments tested in this trial
- Nivolumab
- Ipilimumab
- Cabozantinib
- Transarterial Chemoembolization
Treatment groups
35 Participants
are divided into 1 treatment groupLocations
1Chao Family Comprehensive Cancer Center, University of California, Irvine92868, OrangeCalifornia, United States
Sponsors and collaborators
University of California, Irvine
Lead sponsor
Exelixis
Collaborator
Source ClinicalTrials.gov